12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cangrelor regulatory update

The Medicines Co. said FDA accepted for review an NDA for IV cangrelor to prevent platelet activation and aggregation in patients undergoing percutaneous coronary intervention (PCI),...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >